Astellas Pharma Inc. (4503.T)
- Previous Close
1,469.00 - Open
1,470.50 - Bid --
- Ask --
- Day's Range
1,468.00 - 1,484.50 - 52 Week Range
1,426.00 - 2,360.50 - Volume
775,700 - Avg. Volume
9,038,718 - Market Cap (intraday)
2.7T - Beta (5Y Monthly) 0.28
- PE Ratio (TTM)
561.74 - EPS (TTM)
2.64 - Earnings Date Apr 25, 2024
- Forward Dividend & Yield 70.00 (4.77%)
- Ex-Dividend Date Mar 28, 2024
- 1y Target Est
2,087.10
Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex's GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan.
www.astellas.com14,484
Full Time Employees
March 31
Fiscal Year Ends
Sector
Industry
Recent News: 4503.T
Performance Overview: 4503.T
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 4503.T
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 4503.T
Valuation Measures
Market Cap
2.63T
Enterprise Value
3.22T
Trailing P/E
554.34
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.72
Price/Book (mrq)
1.75
Enterprise Value/Revenue
2.09
Enterprise Value/EBITDA
19.18
Financial Highlights
Profitability and Income Statement
Profit Margin
0.27%
Return on Assets (ttm)
2.48%
Return on Equity (ttm)
0.27%
Revenue (ttm)
1.54T
Net Income Avi to Common (ttm)
4.2B
Diluted EPS (ttm)
2.64
Balance Sheet and Cash Flow
Total Cash (mrq)
285.44B
Total Debt/Equity (mrq)
58.08%
Levered Free Cash Flow (ttm)
58.09B
Research Analysis: 4503.T
Company Insights: 4503.T
4503.T does not have Company Insights